Karin Gaensler, MD

Hematologist

A specialist in hematology-oncology, Dr. Karin Gaensler has a special interest in gene therapy. She is currently working to develop novel approaches for the treatment of blood disorders caused by a specific gene mutation.

Gaensler earned her medical degree from Harvard Medical School. She then went on to complete her residency in internal medicine and a fellowship in hematology-oncology at the University of California, San Francisco. She is the recipient of numerous awards, including the American Cancer Society Fellowship, Howard Hughes Fellowship and NIH Physician Scientist Award.

Clinics

Hematology and Blood and Marrow Transplant
400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051
Fax: (415) 353-2467

Hours: Monday to Friday, 8 a.m. - 5 p.m

Conditions & Treatments

Academic Title

Professor

More about Karin Gaensler

Additional Languages

French
German
Swedish

Education

Harvard Medical School 1981

Residencies

UCSF, Medicine 1984

Fellowships

UCSF, Oncology 1987
UCSF, Hematology 1987

Selected Research and Publications

  1. Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Jun; 22(6):1030-1036.
  2. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Leuk Lymphoma. 2016 07; 57(7):1560-6.
  3. Ikuta T, Sellak H, Odo N, Adekile AD, Gaensler KM. Nitric Oxide-cGMP Signaling Stimulates Erythropoiesis through Multiple Lineage-Specific Transcription Factors: Clinical Implications and a Novel Target for Erythropoiesis. PLoS One. 2016; 11(1):e0144561.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.